Tier 3 — preclinical

The Beneficial Role of Apigenin against Cognitive and Neurobehavioural Dysfunction: A Systematic Review of Preclinical Investigations

Tosin A. Olasehinde, Oyinlola O. Olaokun
Biomedicines 2024 12(1):178

Bibliography

PubMed
PMID 38255283
PubMed Central
PMC10813036
DOI
10.3390/biomedicines12010178
Funding
The authors stated that the research received no external funding.
Competing interests
The authors declared no conflict of interest.

Study snapshot

DesignSystematic review of preclinical investigations using PRISMA methods
ModelRat and mouse models of cognitive and neurobehavioural impairment
Sample34 preclinical studies were reported as included in the review.
InterventionIsolated apigenin at varying doses and durations versus control conditions in rodent models.
DurationVaried across included studies.
EndpointsLearning and memory; Locomotor activity; Anxiety-like behavior; Depressive-like behavior; Sensorimotor function; Motor coordination; ERK/CREB/BDNF signaling; Neuroinflammation and oxidative stress

What the study showed, in plain terms

This systematic review pulled together rodent studies of isolated apigenin and cognition or behavior. Across the included animal models, apigenin was commonly associated with better learning and memory, reduced anxiety- or depression-like behavior and improved motor outcomes. The authors explicitly call for clinical experiments before therapeutic conclusions are made.

Key findings

The review reports favorable effects across learning, memory, locomotion, anxiety-like behavior, depressive-like behavior and motor coordination in impaired rodents. Proposed mechanisms include ERK/CREB/BDNF signaling, neurotransmitter modulation, lower inflammatory signaling and reduced oxidative neuronal damage.

What this study can and cannot tell us

All included efficacy studies were preclinical. Doses, disease models, behavioral tests and intervention durations varied, and animal behavioral improvements cannot establish cognitive or psychiatric benefit in humans. Effective and safe human dosing remains unknown.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology